Tiziana Life Sciences Ltd
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $136.2M
- Price
- $1.07
- % Change (Daily % change from the live per-ticker quote feed.)
- -4.46%
- Volume
- 2.1M
About
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.
Quick stats
Shares outstanding127.3M
Computed float64.8M
Float / shares50.9%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001723069
AI Summary
AI-generated1/34
minorbullishinsider transaction
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
CEO Ivor Elrifi purchased 321,423 common shares at $1.00 per share, increasing his total holdings to 4,793,684 shares.
The company provided an update on its lead candidate intranasal foralumab, noting that 14 patients in an expanded access program showed disease improvement or stability within six months.
A Phase 2a randomized, double-blind trial is currently ongoing to further evaluate the treatment in non-active secondary progressive multiple sclerosis.